Pharmacological analysis and molecular cloning of the canine equilibrative nucleoside transporter 1

European Journal of Pharmacology

Volumn 491, Issue 1, 2004, Pages 9-19

  Hammond, James R ^a   Stolk, Meaghan ^a   Archer, Richard G E ^a   McConnell, Kristy ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Adenosine; Dipyridamole; Draflazine; Nitrobenzylthioinosine; Transporter

Indexed keywords

COMPLEMENTARY DNA; DIPYRIDAMOLE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FORMYCIN B; NITROBENZYLTHIOINOSINE;

ANIMAL CELL; ARTICLE; DOG; DRUG BINDING; DRUG UPTAKE; KIDNEY CELL; MOLECULAR CLONING; NONHUMAN; NUCLEOSIDE TRANSPORT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE;

AMINO ACID SEQUENCE; ANIMALS; BINDING, COMPETITIVE; CARRIER PROTEINS; CELL LINE; CLONING, MOLECULAR; DILAZEP; DIPYRIDAMOLE; DNA, COMPLEMENTARY; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FORMYCINS; KINETICS; MOLECULAR SEQUENCE DATA; PIPERAZINES; PROTEIN BINDING; PROTEIN CONFORMATION; RADIOLIGAND ASSAY; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY, AMINO ACID; STRUCTURE-ACTIVITY RELATIONSHIP; THIOINOSINE; TRITIUM;

EID: 4644279370     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.03.026     Document Type: Article

References (38)

1. Baldwin S.A., Mackey J.R., Cass C.E., Young J.D. Nucleoside transporters: molecular biology and implications for therapeutic development. Mol. Med. Today. 5:1999;216-224.
2. Belt J.A., Marina N.M., Phelps D.A., Crawford C.R. Nucleoside transport in normal and neoplastic cells. Adv. Enzyme Regul. 33:1993;235-252.
3. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22:1973;3099-3108.
4. Crawford C.R., Patel D.H., Naeve C., Belt J.A. Cloning of the human equilibrative, nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line. J. Biol. Chem. 273:1998;5288-5293.
5. Deussen A. Metabolic flux rates of adenosine in the heart. Naunyn-Schmiedeberg's Arch. Pharmacol. 362:2000;351-363.
6. Dunwiddie T.V., Masino S.A. The role and regulation of adenosine in the central nervous system. Annu. Rev. Neurosci. 24:2001;31-55.
7. Flameng W., Sukehiro S., Mollhoff T., Van Belle H., Janssen P. A new concept of long-term donor heart preservation: nucleoside transport inhibition. J. Heart Lung Transplant. 10:1991;990-998.
8. Griffiths M., Beaumont N., Yao S.Y.M., Sundaram M., Boumah C.E., Davies A., Kwong F.Y.P., Coe I., Cass C.E., Young J.D., Baldwin S.A. Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat. Med. 3:1997;89-93.
9. Griffiths M., Yao S.Y., Abidi F., Phillips S.E., Cass C.E., Young J.D., Baldwin S.A. Molecular cloning and characterization of a nitrobenzylthioinosine- insensitive (ei) equilibrative nucleoside transporter from human placenta. Biochem. J. 328:1997;739-743.
10. 3H]nitrobenzylthioinosine binding site. Mol. Pharmacol. 39:1991;771-779.
11. Hammond J.R. Interaction of a series of draflazine analogues with equilibrative nucleoside transporters: species differences and transporter subtype selectivity. Naunyn-Schmiedeberg's Arch. Pharmacol. 361:2000;373-382.
12. Hammond J.R., Archer R.G. Interaction of the novel adenosine uptake inhibitor 3-[1-(6,7-diethoxy-2-morpholinoquinazolin-4-yl)piperidin-4-yl]-1,6- dimethyl-2,4(1H,3H)-quinazolinedione hydrochloride (KF24345) with the es and ei subtypes of equilibrative nucleoside transporters. J. Pharmacol. Exp. Ther. 308:2004;1083-1093.
13. 3H]nitrobenzylthioinosine to the nucleoside transport system in mammalian central nervous system membranes: evidence for interconvertible conformations of the binding site/transporter complex. J. Neurochem. 45:1985;527-535.
14. Handa M., Choi D., Caldeiro R.M., Messing R.O., Gordon A.S., Diamond I. Cloning of a novel isoform of the mouse NBMPR-sensitive equilibrative nucleoside transporter (ENT1) lacking a putative phosphorylation site. Gene. 262:2001;301-307.
15. Hyde R.J., Cass C.E., Young J.D., Baldwin S.A. The ENT family of eukaryote nucleoside and nucleobase transporters: recent advances in the investigation of structure/function relationships and the identification of novel isoforms. Mol. Membr. Biol. 18:2001;53-63.
16. Jarvis S.M., Hammond J.R., Paterson A.R.P., Clanachan A.S. Species differences in nucleoside transport. Biochem. J. 208:1982;83-88.
17. Jarvis S.M., McBride D., Young J.D. Erythrocyte nucleoside transport: asymmetrical binding of nitrobenzylthioinosine to nucleoside permeation sites. J. Physiol. (Lond.). 324:1982;31-46.
18. Kiss A., Farah K., Kim J., Garriock R.J., Drysdale T.A., Hammond J.R. Molecular cloning and functional characterization of inhibitor-sensitive (mENT1) and inhibitor-resistant (mENT2) equilibrative nucleoside transporters from mouse brain. Biochem. J. 352(Pt. 2):2000;363-372.
19. Mackey J.R., Baldwin S.A., Young J.D., Cass C.E. Nucleoside transport and its significance for anticancer drug resistance. Drug Resist. Updat. 1:1998;310-324.
20. Mangravite L.M., Lipschutz J.H., Mostov K.E., Giacomini K.M. Localization of GFP-tagged concentrative nucleoside transporters in a renal polarized epithelial cell line. Am. J. Physiol., Renal Physiol. 280:2001;F879-F885.
21. Mubagwa K., Flameng W. Adenosine, adenosine receptors and myocardial protection: an updated overview. Cardiovasc. Res. 52:2001;25-39.
22. Plagemann P.G.W., Woffendin C. Species differences in sensitivity of nucleoside transport in erythrocytes and cultured cells to inhibition by nitrobenzylthioinosine, dipyridamole, dilazep, and lidoflazine. Biochim. Biophys. Acta. 969:1988;1-8.
23. Ritzel M.W., Ng A.M., Yao S.Y., Graham K., Loewen S.K., Smith K.M., Hyde R.J., Karpinski E., Cass C.E., Baldwin S.A., Young J.D. Recent molecular advances in studies of the concentrative Na+-dependent nucleoside transporter (CNT) family: identification and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). Mol. Membr. Biol. 18:2001;65-72.
24. SenGupta D.J., Lum P.Y., Lai Y., Shubochkina E., Bakken A.H., Schneider G., Unadkat J.D. A single glycine mutation in the equilibrative nucleoside transporter gene, hENT1, alters nucleoside transport activity and sensitivity to nitrobenzylthioinosine. Biochemistry. 41:2002;1512-1519.
25. Sundaram M., Yao S.Y., Ng A.M., Griffiths M., Cass C.E., Baldwin S.A., Young J.D. Chimeric constructs between human and rat equilibrative nucleoside transporters (hENT1 and rENT1) reveal hENT1 structural domains interacting with coronary vasoactive drugs. J. Biol. Chem. 273:1998;21519-21525.
26. Sundaram M., Yao S.Y., Ingram J.C., Berry Z.A., Abidi F., Cass C.E., Baldwin S.A., Young J.D. Topology of a human equilibrative, nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter (hENT1) implicated in the cellular uptake of adenosine and anti-cancer drugs. J. Biol. Chem. 276:2001;45270-45275.
27. Sundaram M., Yao S.Y., Ng A.M., Cass C.E., Baldwin S.A., Young J.D. Equilibrative nucleoside transporters: mapping regions of interaction for the substrate analogue nitrobenzylthioinosine (NBMPR) using rat chimeric proteins. Biochemistry. 40:2001;8146-8151.
28. Tabrizchi R., Bedi S. Pharmacology of adenosine receptors in the vasculature. Pharmacol. Ther. 91:2001;133-147.
29. Van Belle H. Nucleoside transport inhibition: a therapeutic approach to cardioprotection via adenosine? Cardiovasc. Res. 27:1993;68-76.
30. Van Belle H. Myocardial protection by nucleoside transport inhibition. Transplant. Proc. 27:1995;2804-2805.
31. Vickers M.F., Mani R.S., Sundaram M., Hogue D.L., Young J.D., Baldwin S.A., Cass C.E. Functional production and reconstitution of the human equilibrative nucleoside transporter (hENT1) in Saccharomyces cerevisiae. Interaction of inhibitors of nucleoside transport with recombinant hENT1 and a glycosylation-defective derivative (hENT1/N48Q). Biochem. J. 339:1999;21-32.
32. Visser F., Vickers M.F., Ng A.M., Baldwin S.A., Young J.D., Cass C.E. Mutation of residue 33 of human equilibrative nucleoside transporters 1 and 2 alters sensitivity to inhibition of transport by dilazep and dipyridamole. J. Biol. Chem. 277:2002;395-401.
33. Vyas S., Ahmadi B., Hammond J.R. Complex effects of sulfhydryl reagents on ligand interactions with nucleoside transporters: evidence for multiple populations of ENT1 transporters with differential sensitivities to N-ethylmaleimide. Arch. Biochem. Biophys. 403:2002;92-102.
34. Ward J.L., Sherali A., Mo Z.P., Tse C.M. Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. ENT2 exhibits a low affinity for guanosine and cytidine but a high affinity for inosine. J. Biol. Chem. 275:2000;8375-8381.
35. Williams E.F., Barker P.H., Clanachan A.S. Nucleoside transport in heart: species differences in nitrobenzylthioinosine binding, adenosine accumulation, and drug-induced potentiation of adenosine action. Can. J. Physiol. Pharm. 62:1984;31-37.
36. Yang X., Zhu Q., Claydon M.A., Hicks G.L. Jr., Wang T. Enhanced functional preservation of cold-stored rat heart by a nucleoside transport inhibitor. Transplantation. 58:1994;28-34.
37. Yao S.Y., Ng A.M., Muzyka W.R., Griffiths M., Cass C.E., Baldwin S.A., Young J.D. Molecular cloning and functional characterization of nitrobenzylthioinosine (NBMPR)-sensitive (es) and NBMPR-insensitive (ei) equilibrative nucleoside transporter proteins (rENT1 and rENT2) from rat tissues. J. Biol. Chem. 272:1997;28423-28430.
38. Yao S.Y., Ng A.M., Vickers M.F., Sundaram M., Cass C.E., Baldwin S.A., Young J.D. Functional and molecular characterization of nucleobase transport by recombinant human and rat equilibrative nucleoside transporters 1 and 2. Chimeric constructs reveal a role for the ENT2 helix 5-6 region in nucleobase translocation. J. Biol. Chem. 277:2002;24938-24948.